SINGAPORE, October 2022 /PRNewswire/ -- Oncoshot and internationally recognised contract research
Novotech has recently been benchmarked as a top 10 CRO among the world’s leading CROs, is a final
Novotech, the leading Asia Pacific biotech specialist CRO, and GlobalData have published the late
Owing to a large and ageing population base, Asia accounts for more than 60% of the estimated global cases of glaucoma.
Asia-Pacific region accounts for 51% of all blindness cases and 56% of cases of visual impairment worldwide due to Diabetic Retinopathy
According to estimates, 1-2 cases per million people develop PNH annually in Western nations, while the rate is roughly 10 per million each year in Asia, with China and India showing the highest in
Arsalan Arif here with Endpoints News.
CHIEF MEDICAL OFFICER, BIOHENG
With experienced clinical teams in both regions, Novotech will share real-world success strategies for biot
Early clinical-stage US biotech DiaMedica engaged Novotech to provide CRO services and help it take advantage o
Clinical Data Management (CDM) is an integral part of clinical trials and enables clinical trial staff to extract valuable, accurate, high-quality data during the clinical trial process.
While drugs and devices differ in their development, clinical trial phases and regulatory guidelines, the most import
Novotech’s Medical and Regulatory Consulting team offers full range of pre-clinical, regulatory affairs support, medical and pharmacovigilance consulting services.
Novotech relies on years of experience, in-country knowledge and real-life big data to identify and propose the best-performing sites for your study.
Australia is a preferred destination for early phase trials because of simple and fast regulatory stream and lucrative R&D cash refund scheme.
Novotech’s streamlined and integrated clinical trial services are delivered by a dedicated team of professionals with deep industry and therapeutic area expertise across all phases of clinical development.
Delivering accurate, high-quality and timely biostatistics in clinical trials services, including statistical planning, analysis and reporting.
How virtual clinical trials can offer patient retention and cost benefits compared to traditional trials.
Accelerating patient recruitment and drug development with real world data (RWD)
Our bioanalytical services assist our customers in every stage of their molecule development.
Our MISSION is to create career development opportunity for everyone.
The landscape of Oncology in Asia-Pacific
Biotechnology companies are facing increased challenges around participant recruitment and retention, lengthy timeframes and relatively high cost
Our team can assist in all clinical study phases and in study designs ranging from first in human, single ascending dose, multiple ascending dose, drug-drug interaction, bioavailability/bioequivalence, food effect and special population studies.
Starting Your Clinical Journey with the End in Mind – the Value of a Drug Development Plan
Establishing an intelligent clinical development program pathway from the start
Novotech initiated the first national, privately owned, commercial Institutional Biosafety Committee (IBC) in Australia, successfully accredited by the Australian Office of the Gene Technology Reg
Novotech BioDesk provides expert consulting to biotechnology companies with regard to development and realisation of their Drug Development Plans (DDP) and global regulatory strategies driven by a
The landscape of Liver diseases in Asia-Pacific
Biotechnology companies consider locations in the Asia-Pacific region, such as South Korea and China to access vast treatm
Providing Infectious diseases services and Vaccines CRO services
Many biotechnology companies look at the Asia-Pacific region for their trials in Infectious diseases and Vaccines due to t
Landscape of Rare and Orphan diseases in Asia-Pacific
There may be as many as 8,000 rare diseases, affecting between 6% and 8% of the worldwide population in total.
Many biotechnology companies come to Australia to conduct early phase clinical trials and take advantage of straightforward regulatory streams and of the lucrative 43.5% R&D cash refund scheme.